{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:52Z","timestamp":1793896492198,"version":"4.8.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients aged \u226565 years. In this final analysis, 85 patients (median age, 71 years) were followed up for a median of 41.8\u00a0months. The CAVEAT induction combined cytarabine and idarubicin with 5 dose levels of venetoclax (50-600\u00a0mg) for up to 14\u00a0days. Two additional cohorts explored adjusted-dose venetoclax (50\u00a0mg and 100\u00a0mg) with posaconazole. CAVEAT induction was well tolerated, with low mortality (4%) and limited high-grade gastrointestinal toxicity (4%). Delayed hematologic recovery after consolidation was ameliorated by omitting idarubicin from postremission therapy. The overall response rate (ORR; complete response [CR]\u00a0+ CR with partial hematologic recovery\u00a0+ CR with incomplete count recovery) was 75%, with a median overall survival (OS) of 19.3\u00a0months (95% confidence interval [CI], 11.1-31.3). Among de novo AML, ORR was 88% and median OS was 33.1\u00a0months (95%\u00a0CI, 19.3-54.3). Almost one-third have not relapsed, many benefiting from prolonged treatment-free remission (median, 17.9\u00a0months). CAVEAT induction was well tolerated and associated with high ORR that was durable, particularly for de novo AML. CAVEAT represents an effective time-limited treatment option for fit, older patients with AML. This trial was registered at https:\/\/www.anzctr.org.au as #ACTRN12616000445471.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014900","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T09:57:10Z","timestamp":1737194230000},"page":"1827-1835","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)"],"prefix":"10.1182","volume":"9","author":[{"given":"Chong Chyn","family":"Chua","sequence":"first","affiliation":[{"name":"1Department of Haematology, Monash Hospital and Monash University, Melbourne, Australia"},{"name":"2Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"3Department of Clinical Haematology, Northern Hospital, Melbourne, Australia"},{"name":"4Malignant Haematology and Stem Cell Transplant Service, Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-2691","authenticated-orcid":false,"given":"Sun","family":"Loo","sequence":"additional","affiliation":[{"name":"2Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"3Department of Clinical Haematology, Northern Hospital, Melbourne, Australia"},{"name":"5Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-103X","authenticated-orcid":false,"given":"Chun Yew","family":"Fong","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Austin Health, Melbourne, Australia"},{"name":"7Olivia Newton John Cancer Research Institute, Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7755-8326","authenticated-orcid":false,"given":"Stephen B.","family":"Ting","sequence":"additional","affiliation":[{"name":"8Department of Haematology, Eastern Health and Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4343","authenticated-orcid":false,"given":"Ing Soo","family":"Tiong","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"9Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"additional","affiliation":[{"name":"4Malignant Haematology and Stem Cell Transplant Service, Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2093-1403","authenticated-orcid":false,"given":"Natasha S.","family":"Anstee","sequence":"additional","affiliation":[{"name":"2Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"10Department of Medical Biology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ivey","sequence":"additional","affiliation":[{"name":"4Malignant Haematology and Stem Cell Transplant Service, Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-4844","authenticated-orcid":false,"given":"Michael","family":"Ashby","sequence":"additional","affiliation":[{"name":"4Malignant Haematology and Stem Cell Transplant Service, Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Chieh","family":"Teh","sequence":"additional","affiliation":[{"name":"4Malignant Haematology and Stem Cell Transplant Service, Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"},{"name":"8Department of Haematology, Eastern Health and Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-8625","authenticated-orcid":false,"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"4Malignant Haematology and Stem Cell Transplant Service, Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"2Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"5Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"11Centre for Cancer Research, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"2Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"5Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"10Department of Medical Biology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"7","key":"2025042208413868400_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2025042208413868400_bib2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"30","key":"2025042208413868400_bib3","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025042208413868400_bib4","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1182\/blood-2007-02-069666","article-title":"Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial","volume":"109","author":"Gardin","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2025042208413868400_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025042208413868400_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Therapeut"},{"issue":"4","key":"2025042208413868400_bib7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"2025042208413868400_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025042208413868400_bib9","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1182\/blood-2023-180491","article-title":"Prospective pharmacokinetic evaluation of venetoclax (VEN) in AML demonstrates significant and variable drug interactions with azole antifungals that increase ven exposure, reduce clearance, and necessitate re-evaluation of dose adjustments","volume":"142","author":"Kawedia","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025042208413868400_bib10","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/pharmaceutics15061680","article-title":"Pharmacokinetics of venetoclax co-administered with posaconazole in patients with acute myeloid leukemia","volume":"15","author":"De Gregori","year":"2023","journal-title":"Pharmaceutics"},{"issue":"suppl 16","key":"2025042208413868400_bib11","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1200\/JCO.2024.42.16_suppl.6519","article-title":"FLAG-IDA+ venetoclax in newly diagnosed (ND) or relapsed\/refractory (RR) AML [abstract]","volume":"42","author":"Jen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025042208413868400_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1248\/yakushi.24-00018","article-title":"Plasma venetoclax concentrations in patients with acute myeloid leukemia treated with CYP3A4 inhibitors","volume":"144","author":"Otsuki","year":"2024","journal-title":"Yakugaku Zasshi"},{"issue":"26","key":"2025042208413868400_bib13","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1827\/2367662\/blooda_adv-2024-014900-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1827\/2367662\/blooda_adv-2024-014900-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:41:45Z","timestamp":1745311305000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/1827\/535194\/Final-analysis-of-the-phase-1b-Chemotherapy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014900","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}